Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

As NuVasive Stock Sinks, Its CEO Keeps Sinking Money Into It

As shares of medical device-maker NuVasive (NASDAQ:NUVA) soared towards a recent 52-week high of $51.25, sales by company insiders likewise ran amok. But one inside shareholder in particular isn’t joining in the selling.

Instead, NuVasive’s CEO is buying.

According to Form 4 filings with the SEC, NuVasive insiders have placed a total of 14 sell orders over the past three months, against only six buys. In total, these insiders have sold 167,873 more shares than they have bought. Helping to offset all the selling, however, have been a series of “indirect” and “automatic” purchase orders by company Chairman and CEO Mr. Gregory T. Lucier.

Lucier’s buying spree began with a 34,000 indirect acquisition of NuVasive shares on May 28, 2015, which more than doubled his stake in the company. Subsequent acquisitions of 3,000 shares on June 1, then 5,000 share batches acquired respectively on June 2, 3, and 4, grew Lucier’s stake to its last-reported level of 80,000 shares. Each of these last four purchases, placed as prices slid from $50.25 down to $49.67, were characterized as “automatic” buys.

What does it mean to you?
NuVasive shares have continued to slide since Lucier’s purchases ceased, closing Monday at $49 (a price that still leaves NuVasive shares up 42% over the past year, against just a 7% rise for the S&P 500). At this price, NuVasive shares sell for more than 71 times earnings and 3 times sales.

If those valuations seem high, it’s because they are. NuVasive, which pays no dividend, and is pegged for only 15% long-term earnings growth by analysts who follow it. That works out to a PEG ratio on the stock of roughly 4.7 (hint: value investors generally try to buy shares that sell for a price-to-earnings-to-growth ratio of 1.0 or less).

Little wonder, then, that analysts at Goldman Sachs removed their “buy” rating on the stock last week. Little wonder that most insiders are selling. In fact, the only remarkable thing here, really, is that NuVasive’s CEO continues to sink his own money into the stock — but then again, seeing as his purchases are “automatic,” maybe he really has no say in the matter.


The next billion-dollar Apple secret
Apple forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn’t miss a beat: There’s a small company that’s powering Apple’s brand-new gadgets and the coming revolution in technology. And its stock price has nearly unlimited room to run for early-in-the-know investors! To be one of them, just click here.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!